Vaccines and infectious diseases

Meridian is a leader in high-volume vaccine trials and research programs that require hard-to-reach patients.

The majority of the world’s leading Sponsors and CROs have made Meridian a strategic partner for their infectious disease research programs. Meridian provides a broad national footprint to support rapid enrollment, even for studies involving sensitive cohorts (e.g., seniors, children, at-risk populations).

Several of Meridian’s principal investigators are also sought after by Sponsors and CROs to guide vaccine-related protocol development. These investigators have had research published in prestigious industry journals, including Vaccine.

Patient Receiving Vaccine
Vaccine clinical trials conducted
Average enrollment for vaccine trials
Participants enrolled into vaccine trials

Therapeutic experience

  • Anthrax
  • Chikungunya
  • C. difficile
  • Cytomegalovirus (CMV)
  • Dengue fever
  • Ebola
  • Encephalitis
  • H1N1, H5N1, and H7N9
  • Herpes
  • Human metapneumovirus (hMPV)
  • Human papillomavirus (HPV)
  • Influenza, including pediatric, geriatric, and off-season
  • Lyme disease
  • Meningococcal
  • mRNA vaccines
  • Parainfluenza
  • Pediatric meningitis
  • Pediatric influenza
  • Plague
  • Pneumococcal
  • Rabies
  • Respiratory syncytial virus (RSV), including maternal and pediatric
  • SARS-CoV-2 (COVID-19)
  • Smallpox
  • Type 3 (PIV3)/RSV combo
  • West Nile virus
  • Zika virus

COVID-19 clinical trial performance

In 2020, Meridian supported 30 Phase 2 and 3 trials for vaccines, prophylaxes, diagnostics, and medications.

COVID-19 vaccine trial patients enrolled


The proven site network for novel vaccine research programs

Across any indication, including anti-infectives and immunologics, Meridian is prepared to support your research program for a novel vaccine, diagnostic, or combination product.

In-house monitoring, quality assurance, and audit support

PBMC processing capabilities and central laboratory support

Government-funded, Phase I, and first-in-human trial experience

2020 Vaccine Industry Excellence (ViE) award winner for Best Clinical Trial Site, Best Clinical Trial Network

Featured vaccine investigators

Brandon Essink, MD, CPI

Brandon Essink, MD, CPI

  • Meridian Chief Medical Officer, Principal Investigator since 2003
  • Frequently selected to lead pioneering vaccine research programs
  • Results from clinical studies frequently published in industry journals (recently in Vaccine)
Keith Vrbicky, MD

Keith Vrbicky, MD

  • Meridian Principal Investigator since 2013 in Norfolk, NE
  • Highly-respected physician in his region; frequently published for expertise in maternal vaccination trials
  • Sought after speaker, prominent figure in research for women's health, pediatrics, vaccines
  • Delivered 13,500+ babies
Andrew Kimball

Connect with Andrew Kimball, Chief Commercial Officer at Meridian

Let's talk about your next trial